Hertin und Partner Rechts- und Patentanwälte PartG mbB

Die Erfindung betrifft ein Deckenelement für eine Gebäudedecke. Das Deckenelement ist als Holz-Beton-Verbund ausgebildet. Das Deckenelement umfasst ein Holzbauteil aufweisend eine oder mehrere Formstrukturen, ein Betonbauteil umfassend eine Elementdecke und eine Ortbetonergänzung, einen Gitterträger, ein Verbindungsmittel und eine Hülse. Das Verbindungsmittel ist in die Hülse eingebracht. Das Betonbauteil ist mit dem Holzbauteil über das Verbindungsmittel und/oder die Formstruktur verbunden. Weiterhin betrifft die Erfindung ein Verfahren zur Herstellung des Deckenelementes.

The invention relates to a system for storage and production of electrical energy, wherein electrical energy is converted to thermal energy for storage, and thermal energy is converted to electrical energy for production. CO<2> is stored temporarily and/or permanently in a geological formation. The system comprises a surface portion and a subsurface portion. The subsurface portion comprises at least one underground reservoir, which is configured for temporary and/or permanent CO<2> storage. It has at least one caprock layer positioned above the reservoir and at least one well in communication with the at least one reservoir and the surface portion. The surface portion comprises a charging cycle, which is configured for storage of electrical energy, a discharging cycle, which is configured for production of electrical energy, and means for thermal energy storage. The subsurface portion and the surface portion are in communication with each other via a working fluid.

The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container comprising at least one selenium compound in the form of Se(IV), characterized in that the solution comprises dissolved oxygen (DO).

Die Erfindung betrifft ein Verfahren zur Herstellung einer nicht-flüssigen Mahlerzeugnis-Zusammensetzung für die Herstellung einer flüssigen Mahlerzeugnis-Zusammensetzung, umfassend (i.) Bereitstellen einer Paste enthaltend ein Mahlerzeugnis, Wasser und ein Pflanzenfett, wobei die Paste 5 bis 50 Gew.-% Wasser und 2 bis 10 Gew.-% Pflanzenfett enthält, bezogen auf das Gesamtgewicht der Paste, (ii.) Formen der Paste (i.) zu einem Strang. In einem weiteren Aspekt betrifft die Erfindung eine Mahlerzeugnis-Zusammensetzung zur Auflösung und/oder Dispergierung in einer verzehrbaren Flüssigkeit hergestellt und/oder herstellbar mittels des Verfahrens der vorliegenden Erfindung, dadurch gekennzeichnet, dass die Mahlerzeugnis-Zusammensetzung 5 bis 15 Gew.-% Wasser und 2 bis 10 Gew.-% Pflanzenfett enthält. In einem weiteren Aspekt betrifft die Erfindung eine Lebensmittel-Zusammensetzung zur Auflösung und/oder Dispergierung in einer verzehrbaren Flüssigkeit enthaltend eine Mahlerzeugnis-Zusammensetzung hergestellt und/oder herstellbar mittels des Verfahrens der vorliegenden Erfindung. In einem weiteren Aspekt betrifft die Erfindung eine flüssige Mahlerzeugnis-Zusammensetzung hergestellt durch Auflösen und/oder Dispergieren der Mahlerzeugnis-Zusammensetzung der vorliegenden Erfindung in einer verzehrbaren Flüssigkeit.

The invention relates to a method for analyzing a sample comprising one or more molecules of interest by a mass spectrometer, comprising ionizing a multitude of molecules and/or fragments thereof comprised within a sample to obtain a multitude of molecule ions (source ions), and performing mass spectrometry (MS) analysis comprising a. analyzing the molecule ions and/or fragments thereof in a MS1 measurement, thereby acquiring ion mass spectral data of at least a fraction of the molecule ions and/or fragments thereof (source ions) comprising their mass to charge ratio (m/z), b./c. isolating a first fraction and a second of the molecule ions (precursor ions) having a m/z within a first m/z range (mz1; isolation window) and a second m/z range (mz2; isolation window), using a mass filter device, wherein the first m/z range is selected based on the ion mass spectral data acquired in step a. or one or more iterations of step a. and/or e., and wherein the second m/z range (mz2) overlaps with the first m/z range (mz1), d. fragmenting at least a fraction of the molecule ions (precursor ions) isolated in steps b. and c., separately, to obtain a multitude of biomolecule fragment ions from each of the respective fragmented molecule ions (precursor ions), and e. analyzing the multitude of biomolecule fragment ions in one or more MS2 measurement, thereby acquiring ion mass spectral data of the analyzed biomolecule fragment ions.

The invention relates to a blood treatment device configured to dephosphorylate extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and/or lipopolysaccharide (LPS) in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix having alkaline phosphatase (AP) immobilized thereon. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating an infection, preferably a blood or systemic infection, such as sepsis, and/or for the treatment of sepsis-associated acute kidney injury (AKI).

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container characterized in that the solution comprises at least one of a selenate salt and/or a seleno-amino acid, such as selenomethionine or selenocysteine.

The invention relates to a tracer compound for whole-cell labelling, comprising: a non-streptavidin-binding biotin analogue, at least one connecting moiety comprising a functional group configured for a click-chemistry reaction, and at least one cross-linkable moiety, preferably wherein the cross-linkable moiety is a (para)formaldehyde cross-linkable group, and the non-streptavidin-binding biotin analogue enables the tracer compound to diffuse within a biological cell with essentially the same properties as biocytin and/or neurobiotin, preferably enabling the detection of cellular protrusions, such as dendrites, dendritic spines and axons. The invention further relates to methods for constructing such tracer compound and for labelling a cell therewith. The invention further relates to kits for carrying out the method according to the invention.